Gono T, Masui K, Nishina N, et al. - In the present study, the researchers sought to create predictive models for mortality in patients with polymyositis/dermatomyositis–associated interstitial lung disease (PM/DM‐ILD) using a combination of initial serum biomarker levels. The derivation cohort was 497 incident cases of PM/DMILD from the Multicenter Retrospective Cohort of Japanese Patients with Myositis Associated ILD (JAMI) database, and 111 cases were collected as a validation cohort. The results suggest that an evidence‐based risk prediction model using CRP and KL‐6 levels combined with anti–MDA‐5 antibody status may be useful in predicting prognosis in PM/DM‐ILD patients.